​

Editas Medicine (EDIT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

EDIT Stock Forecast

Editas Medicine stock forecast is as follows: an average price target of $10.20 (represents a 678.63% upside from EDIT’s last price of $1.31) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.

EDIT Price Target

The average price target for Editas Medicine (EDIT) is $10.20 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $5.00. This represents a potential 678.63% upside from EDIT's last price of $1.31.

EDIT Analyst Ratings

Buy

According to 12 Wall Street analysts, Editas Medicine's rating consensus is 'Buy'. The analyst rating breakdown for EDIT stock is 0 'Strong Buy' (0.00%), 6 'Buy' (50.00%), 6 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Editas Medicine Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 05, 2024Gena WangBarclays$5.00$3.1260.26%281.68%
Oct 23, 2024Yanan ZhuWells Fargo$9.00$3.29173.56%587.02%
Oct 22, 2024Joel BeattyRobert W. Baird$10.00$3.29203.95%663.36%
Aug 08, 2024Joon LeeTruist Financial$12.00$4.24183.02%816.03%
Aug 08, 2024Greg HarrisonBank of America Securities$15.00$4.21256.72%1045.04%
May 30, 2024Liisa BaykoEvercore ISI$7.00$5.1037.25%434.35%
May 09, 2024Matthew HarrisonMorgan Stanley$7.00$5.0439.03%434.35%
Sep 28, 2023Dae Gon HaStifel Nicolaus$17.00$6.92145.66%1197.71%
Dec 13, 2022Citigroup$11.00$9.9610.44%739.69%
Nov 18, 2022Morgan Stanley$8.00$10.63-24.78%510.69%
Nov 18, 2022RBC Capital$14.00$11.0127.16%968.70%
Nov 18, 2022Joon LeeTruist Financial$35.00$11.01217.89%2571.76%
Nov 18, 2022Oppenheimer$12.00$11.018.99%816.03%
Nov 18, 2022Credit Suisse$13.00$11.0118.07%892.37%
Nov 18, 2022Chardan Capital$35.00$11.01217.89%2571.76%
Jan 06, 2022Matthew HarrisonMorgan Stanley$24.00$24.41-1.68%1732.06%
Nov 08, 2021Joel BeattyRobert W. Baird$44.00$40.578.45%3258.78%
Sep 29, 2021Joon LeeTruist Financial$80.00$42.5088.24%6006.87%

The latest Editas Medicine stock forecast, released on Nov 05, 2024 by Gena Wang from Barclays, set a price target of $5.00, which represents a 60.26% increase from the stock price at the time of the forecast ($3.12), and a 281.68% increase from EDIT last price ($1.31).

Editas Medicine Price Target by Period

1M3M12M
# Anlaysts-37
Avg Price Target-$8.00$9.29
Last Closing Price$1.31$1.31$1.31
Upside/Downside-100.00%510.69%609.16%

In the current month, the average price target of Editas Medicine stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Editas Medicine's last price of $1.31. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 06, 2024Evercore ISIOutperformUpgrade
Nov 05, 2024OppenheimerPerformPerformHold
Nov 05, 2024BarclaysMixedMixedHold
Nov 04, 2024RBC CapitalSector PerformSector PerformHold
Oct 23, 2024Wells FargoSector PerformSector PerformHold
Oct 23, 2024Wells FargoOverweightOverweightHold
Aug 08, 2024Bank of America SecuritiesBuyUpgrade
Jun 18, 2024OppenheimerBuyBuyHold
May 08, 2024Morgan StanleyUnderweightEqual-WeightUpgrade
May 08, 2024CitigroupBuyBuyHold
Oct 17, 2023Cantor FitzgeraldOverweightNeutralDowngrade
Sep 29, 2023Piper SandlerBuyUpgrade
Jun 12, 2023Raymond JamesOutperformUpgrade
Feb 01, 2023Cantor FitzgeraldOverweightInitialise
Jan 04, 2023Wells FargoOverweightOverweightHold
Dec 13, 2022CitigroupNeutralInitialise
Nov 18, 2022Morgan StanleyUnderweightUnderweightHold
Nov 18, 2022OppenheimerOutperformPerformDowngrade
Nov 18, 2022Credit SuisseNeutralDowngrade
Nov 18, 2022Chardan CapitalBuyBuyHold
Feb 25, 2022OppenheimerOutperformOutperformHold
Feb 25, 2022Chardan CapitalBuyBuyHold
Feb 25, 2022SVB LeerinkMarket PerformMarket PerformHold

Editas Medicine's last stock rating was published by Evercore ISI on Nov 06, 2024. The company Upgrade its EDIT rating from "null" to "Outperform".

Editas Medicine Financial Forecast

Editas Medicine Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue---------------$9.85M$6.54M$42.00K$6.36M$6.77M$12.47M$6.20M$379.00K$6.50M$11.42M$62.84M$10.75M$5.72M$12.28M$3.85M
Avg Forecast$103.21K$97.35K$91.83K$86.61K$1.74M$907.63K$782.63K$770.13K$31.70M$3.93M$4.78M$11.14M$3.70M$3.70M$4.17M$3.29M$3.66M$4.39M$4.29M$3.85M$4.64M$4.74M$6.03M$5.83M$5.64M$6.36M$6.34M$6.72M$44.61M$4.76M
High Forecast$282.62K$266.58K$251.44K$237.17K$4.78M$2.49M$2.14M$2.34M$62.89M$10.76M$4.78M$11.14M$15.40M$3.70M$11.42M$9.00M$10.02M$4.39M$4.29M$3.85M$4.64M$4.74M$6.03M$5.83M$5.64M$6.36M$6.34M$6.72M$44.61M$4.76M
Low Forecast$2.64K$2.49K$2.35K$2.21K$44.62K$23.21K$20.02K$142.09K$70.09K$100.48K$4.78M$11.14M$826.63K$3.70M$106.70K$84.03K$93.56K$4.39M$4.29M$3.85M$4.64M$4.74M$6.03M$5.83M$5.64M$6.36M$6.34M$6.72M$44.61M$4.76M
# Analysts4444333511574946437434744633322
Surprise %---------------3.00%1.79%0.01%1.48%1.76%2.69%1.31%0.06%1.12%2.02%9.89%1.70%0.85%0.28%0.81%

Editas Medicine's average Quarter revenue forecast for Jun 23 based on 6 analysts is $4.17M, with a low forecast of $106.70K, and a high forecast of $11.42M. EDIT's average Quarter revenue forecast represents a -57.65% decrease compared to the company's last Quarter revenue of $9.85M (Mar 23).

Editas Medicine EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts4444333511574946437434744633322
EBITDA-------------$-45.02M$-40.29M$-50.96M$-63.45M$-55.92M$-52.64M$-49.19M$-39.92M$-37.89M$-54.07M$-55.56M$-61.32M$8.93M$-23.29M$-38.48M$-38.63M$-33.89M
Avg Forecast$-103.21K$-97.35K$-91.83K$-86.61K$-1.74M$-907.63K$-782.63K$-770.13K$-31.70M$-3.93M$-4.78M$-62.38M$-3.70M$-3.70M$-4.17M$-56.71M$-58.22M$-4.39M$-4.29M$-51.56M$-4.64M$-4.74M$-6.03M$-45.67M$-5.64M$-6.36M$-6.34M$-43.36M$-44.61M$-4.76M
High Forecast$-2.64K$-2.49K$-2.35K$-2.21K$-44.62K$-23.21K$-20.02K$-142.09K$-70.09K$-100.48K$-4.78M$-49.91M$-826.63K$-3.70M$-106.70K$-45.37M$-46.58M$-4.39M$-4.29M$-41.25M$-4.64M$-4.74M$-6.03M$-36.54M$-5.64M$-6.36M$-6.34M$-34.69M$-44.61M$-4.76M
Low Forecast$-282.62K$-266.58K$-251.44K$-237.17K$-4.78M$-2.49M$-2.14M$-2.34M$-62.89M$-10.76M$-4.78M$-74.86M$-15.40M$-3.70M$-11.42M$-68.06M$-69.87M$-4.39M$-4.29M$-61.87M$-4.64M$-4.74M$-6.03M$-54.80M$-5.64M$-6.36M$-6.34M$-52.03M$-44.61M$-4.76M
Surprise %-------------12.16%9.66%0.90%1.09%12.73%12.27%0.95%8.60%8.00%8.97%1.22%10.87%-1.40%3.68%0.89%0.87%7.11%

6 analysts predict EDIT's average Quarter EBITDA for Dec 20 to be $-5.64M, with a high of $-5.64M and a low of $-5.64M. This is -163.22% lower than Editas Medicine's previous annual EBITDA (Sep 20) of $8.93M.

Editas Medicine Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts4444333511574946437434744633322
Net Income-------------$-45.02M$-40.29M$-45.57M$-55.03M$-53.93M$-52.67M$-50.28M$-41.44M$-39.08M$-55.26M$-56.73M$-62.50M$7.82M$-23.57M$-37.72M$-37.77M$-32.94M
Avg Forecast$-21.71M$-21.72M$-21.72M$-21.73M$-28.96M$-30.58M$-34.75M$-41.97M$-26.83M$-61.62M$-58.07M$-64.99M$-49.00M$-47.44M$-63.26M$-59.08M$-60.42M$-70.20M$-66.53M$-53.71M$-58.62M$-66.91M$-67.79M$-46.63M$-62.56M$-51.53M$-64.66M$-42.50M$4.12M$-58.13M
High Forecast$5.79M$5.79M$5.79M$5.80M$7.73M$8.16M$9.27M$-28.43M$46.00M$16.44M$15.49M$-51.99M$19.79M$12.65M$16.87M$-47.27M$-48.34M$-70.20M$-66.53M$-42.97M$-58.62M$-66.91M$-67.79M$-37.30M$-62.56M$-51.53M$-64.66M$-34.00M$4.12M$-58.13M
Low Forecast$-70.77M$-70.80M$-70.80M$-70.82M$-94.41M$-99.68M$-113.27M$-50.10M$-82.42M$-200.86M$-189.30M$-77.99M$-70.67M$-154.63M$-206.20M$-70.90M$-72.51M$-70.20M$-66.53M$-64.45M$-58.62M$-66.91M$-67.79M$-55.95M$-62.56M$-51.53M$-64.66M$-51.00M$4.12M$-58.13M
Surprise %-------------0.95%0.64%0.77%0.91%0.77%0.79%0.94%0.71%0.58%0.82%1.22%1.00%-0.15%0.36%0.89%-9.18%0.57%

Editas Medicine's average Quarter net income forecast for Dec 20 is $-62.56M, with a range of $-62.56M to $-62.56M. EDIT's average Quarter net income forecast represents a -900.05% decrease compared to the company's last Quarter net income of $7.82M (Sep 20).

Editas Medicine SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts4444333511574946437434744633322
SG&A-------------$14.99M$17.20M$23.01M$17.98M$16.24M$16.94M$19.55M$16.53M$16.18M$22.03M$21.45M$15.79M$19.94M$14.08M$17.77M$16.92M$15.73M
Avg Forecast$234.28K$220.99K$208.44K$196.61K$3.96M$2.06M$1.78M$1.75M$71.96M$8.92M$10.85M$25.29M$8.39M$8.41M$9.47M$7.46M$8.30M$9.97M$9.74M$8.75M$10.54M$10.76M$13.68M$13.22M$12.81M$14.43M$14.38M$15.27M$101.27M$10.82M
High Forecast$641.53K$605.13K$570.77K$538.38K$10.84M$5.64M$4.86M$5.32M$142.75M$24.42M$10.85M$25.29M$34.96M$8.41M$25.93M$20.42M$22.74M$9.97M$9.74M$8.75M$10.54M$10.76M$13.68M$13.22M$12.81M$14.43M$14.38M$15.27M$101.27M$10.82M
Low Forecast$5.99K$5.65K$5.33K$5.03K$101.28K$52.70K$45.44K$322.54K$159.11K$228.09K$10.85M$25.29M$1.88M$8.41M$242.22K$190.74K$212.38K$9.97M$9.74M$8.75M$10.54M$10.76M$13.68M$13.22M$12.81M$14.43M$14.38M$15.27M$101.27M$10.82M
Surprise %-------------1.78%1.82%3.09%2.17%1.63%1.74%2.23%1.57%1.50%1.61%1.62%1.23%1.38%0.98%1.16%0.17%1.45%

Editas Medicine's average Quarter SG&A projection for Dec 23 is $8.39M, based on 9 Wall Street analysts, with a range of $1.88M to $34.96M. The forecast indicates a -43.99% fall compared to EDIT last annual SG&A of $14.99M (Sep 23).

Editas Medicine EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts4444333511574946437434744633322
EPS-------------$-0.00$-0.00$-0.66$-0.80$-0.78$-0.77$-0.73$-0.61$-0.57$-0.81$-0.86$-1.00$0.13$-0.43$-0.69$-0.74$-0.66
Avg Forecast$-0.26$-0.26$-0.26$-0.26$-0.35$-0.37$-0.42$-0.51$-0.33$-0.75$-0.70$-0.63$-0.59$-0.58$-0.77$-0.78$-0.79$-0.85$-0.81$-0.78$-0.71$-0.81$-0.82$-0.74$-0.76$-0.63$-0.79$-0.79$0.05$-0.71
High Forecast$0.07$0.07$0.07$0.07$0.09$0.10$0.11$-0.34$0.56$0.20$0.19$0.17$0.24$0.15$0.20$0.21$0.21$-0.85$-0.81$-0.78$-0.71$-0.81$-0.82$-0.74$-0.76$-0.63$-0.79$-0.79$0.05$-0.71
Low Forecast$-0.86$-0.86$-0.86$-0.86$-1.14$-1.21$-1.37$-0.61$-1.00$-2.44$-2.29$-2.04$-0.86$-1.87$-2.50$-2.56$-2.57$-0.85$-0.81$-0.78$-0.71$-0.81$-0.82$-0.74$-0.76$-0.63$-0.79$-0.79$0.05$-0.71
Surprise %-------------0.00%0.00%0.84%1.01%0.91%0.95%0.93%0.86%0.70%0.98%1.16%1.32%-0.21%0.55%0.88%-14.80%0.93%

According to 6 Wall Street analysts, Editas Medicine's projected average Quarter EPS for Dec 20 is $-0.76, with a low estimate of $-0.76 and a high estimate of $-0.76. This represents a -684.62% decrease compared to EDIT previous annual EPS of $0.13 (Sep 20).

Editas Medicine Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
ALLOAllogene Therapeutics$2.07$29.001300.97%Buy
EDITEditas Medicine$1.52$10.20571.05%Buy
PRMEPrime Medicine$2.91$17.25492.78%Buy
SANASana Bio$1.91$8.00318.85%Buy
NTLAIntellia Therapeutics$13.13$53.00303.66%Buy
VERVVerve Therapeutics$5.61$14.00149.55%Buy
BEAMBeam Therapeutics$28.58$55.0092.44%Buy
CRSPCRISPR Therapeutics$44.63$77.5073.65%Buy
CRBUCaribou Biosciences$1.94$3.0054.64%Buy
VRTXVertex Pharmaceuticals$469.24$533.3013.65%Buy
DNAGinkgo Bioworks$9.61$7.00-27.16%Buy

EDIT Forecast FAQ

Is Editas Medicine a good buy?

Yes, according to 12 Wall Street analysts, Editas Medicine (EDIT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 50.00% of EDIT's total ratings.

What is EDIT's price target?

Editas Medicine (EDIT) average price target is $10.2 with a range of $5 to $15, implying a 678.63% from its last price of $1.31. The data is based on 12 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Editas Medicine stock go up soon?

According to Wall Street analysts' prediction for EDIT stock, the company can go up by 678.63% (from the last price of $1.31 to the average price target of $10.2), up by 1045.04% based on the highest stock price target, and up by 281.68% based on the lowest stock price target.

Can Editas Medicine stock reach $2?

EDIT's average twelve months analyst stock price target of $10.2 supports the claim that Editas Medicine can reach $2 in the near future.

What are Editas Medicine's analysts' financial forecasts?

Editas Medicine's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $4.2M (high $11.75M, low $229.94K), average EBITDA is $-4.205M (high $-230K, low $-11.747M), average net income is $-136M (high $-3.281M, low $-357M), average SG&A $9.54M (high $26.66M, low $521.96K), and average EPS is $-1.652 (high $-0.0398, low $-4.334). EDIT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $379K (high $1.04M, low $9.69K), average EBITDA is $-379K (high $-9.692K, low $-1.038M), average net income is $-86.873M (high $23.17M, low $-283M), average SG&A $860.33K (high $2.36M, low $22K), and average EPS is $-1.053 (high $0.281, low $-3.433).

Did the EDIT's actual financial results beat the analysts' financial forecasts?

Based on Editas Medicine's last annual report (Dec 2022), the company's revenue was $19.71M, beating the average analysts forecast of $16.19M by 21.74%. Apple's EBITDA was $-226M, beating the average prediction of $-118M by 90.74%. The company's net income was $-204M, missing the average estimation of $-251M by -18.54%. Apple's SG&A was $70.7M, beating the average forecast of $36.76M by 92.36%. Lastly, the company's EPS was $-2.98, missing the average prediction of $-3.232 by -7.78%. In terms of the last quarterly report (Mar 2023), Editas Medicine's revenue was $9.85M, beating the average analysts' forecast of $3.29M by 199.87%. The company's EBITDA was $-50.961M, missing the average prediction of $-56.713M by -10.14%. Editas Medicine's net income was $-45.567M, missing the average estimation of $-59.083M by -22.88%. The company's SG&A was $23.01M, beating the average forecast of $7.46M by 208.54%. Lastly, the company's EPS was $-0.66, missing the average prediction of $-0.784 by -15.83%